Last updated on February 2019

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NIDDM | Cholesterolemia | Diabetes Mellitus
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Type 2 diabetes for 6 months or greater
  • Currently taking stable diabetes medication for 3 months or greater
  • HbA1c between 7-10%
  • LDL-cholesterol greater than 70 mg/dL
  • Women must not be pregnant, lactating, or planning to become pregnant within 30 days after last dose of study medication; and must be postmenopausal, surgically sterile, or willing to use 1 acceptable form of birth control during the study through 30 days after the last dose of study medication

Exclusion Criteria:

  • Body mass index > 40 kg/m2
  • History of documented clinically significant cardiovascular disease
  • Fasting triglycerides > 400 mg/dL
  • History of Type 1 diabetes
  • Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal condition that may affect drug absorption, hematologic or coagulation disorder or active malignancy
  • History of drug or alcohol abuse within 2 years

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.